Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic… Ended

2024-517061-16-01 Focal onset seizures or primary generalized tonic-cloni 4 2025-02-27
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures Ended

2024-514045-11-00 Partial Onset Seizures 3 2025-02-26
Characterization of Immune Response in Participants from a Posdinemab Study Ended

2024-514634-20-00 Early Alzheimer's disease 3 2025-02-25
A Phase 1, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multi… Ended

2024-515549-40-00 neurological disease 1 2025-02-21
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for … Ended

2023-509257-31-00 Alzheimer’s Disease in Individuals with Down Syndrome 1 2025-02-12
TOXSIALO-TRIAL : Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patc… Ended

2024-512160-58-00 Cerebral palsy with pathological drooling 6 2025-02-12
Study on the investigational drug SAN711, placebo-controlled, administered to healthy adults and elderly subjects at multiple ascending oral… Ended

2024-514514-12-00 Absence Seizure 3 2025-02-12
A PHASE 1B DOSE RANGE FINDING STUDY OF PHENSERINE COMPARED TO DONEPEZIL IN PARTICIPANTS WITH EARLY OR MILD ALZHEIMER’S DISEASE Ended

2023-510282-10-00 Mild Cognitive Impairment 3 2025-02-11
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 Ended

2024-511112-24-00 Narcolepsy Type 1 4 2025-01-17
Dendritic cell therapy combined treatment in multiple sclerosis Ended

2024-519975-24-00 Multiple sclerosis 4 2025-01-13
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants Ended

2024-518833-27-00 Amyotrophic Lateral Sclerosis (ALS) 3 2025-01-10
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and… Ended

2023-504838-21-00 Healthy 1 2025-01-08
A clinical study of MK-6916 in healthy people (MK-6916-002) Ended

2024-516899-15-00 Acute and Chronic Pain 3 2025-01-07
Open-Label Extension of EryDex in A-T (OLE NEAT) Ended

2024-513618-37-00 Ataxia Telangiectasia (A-T) 5 2024-12-23
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigi… Ended

2024-513106-62-00 Bipolar disorder 2 2024-12-16
A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms Ended

2024-513258-31-00 Frontotemporal dementia (FTD) 3 2024-12-11
A clinical study of MK-6916 and placebo in healthy people (MK-6916-003) Ended

2024-516878-30-00 Acute and chronic Pain 3 2024-12-10
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC… Ended

2024-515151-38-00 Nervous System disease 3 2024-12-06
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
First administration of a single and increasing doses of BDT272 to assess its safety and pharmacokinetic in healthy volunteers Ended

2024-515415-22-00 Moderate to severe pain 1 2024-11-25
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics… Ended

2024-512106-26-02 Cognitive impairment 1 2024-11-19
Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN Ended

2024-516773-69-00 central nervous system (CNS) lymphomas 9 2024-11-18
Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With… Ended

2023-508457-10-00 Primary Progressive Multiple Sclerosis 7 2024-11-15
A study to investigate behavioral and other co-occurring outcomes with Epid(i/y)olex as add-on therapy in participants aged 1 to 65 years of… Ended

2023-507426-17-00 Tuberous Scerlosis Complex 11 2024-11-12